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Transmitted mHtt aggregates gave rise to both motor and 
cognitive impairments, loss of striatal medium spiny neu-
rons, increased inflammation and gliosis in associated brain 
regions, thereby recapitulating the behavioural and patho-
logical phenotypes which characterizes HD. In addition, 
both in vitro work using co-cultures of mouse neural stem 
cells with 143 CAG fibroblasts and the SH-SY5Y human 
neuroblastoma cell line as well as in vivo experiments con-
ducted in newborn wild-type mice suggest that exosomes 
can cargo mHtt between cells triggering the manifestation 
of HD-related behaviour and pathology. This is the first evi-
dence of human-to-mouse prion-like propagation of mHtt 
in the mammalian brain; a finding which will help unravel 
the molecular bases of HD pathology as well as to lead to 
the development of a whole new range of therapies for neu-
rodegenerative diseases of the CNS.
Keywords Huntington’s disease · Full-length mutant 
huntingtin · Human fibroblasts · Human-induced 
pluripotent stem cells · Exosomes
Introduction
Prominent neuronal loss typifies neurodegenerative dis-
orders and the presence of abnormally structured or mis-
folded proteins has conferred to these conditions the title 
of proteinopathies. In recent years, a surge of publications 
has consistently reported experimental evidence for the 
spreading of such abnormal proteins, including β-amyloid, 
Tau, SOD1, TDP-43 and FUS [22, 44]. It was perhaps 
the more recent observation of Lewy body pathology in 
patients with Parkinson’s disease (PD) in receipt of fetal 
ventral mesencephalic transplants [23, 24] that propelled 
the theory that pathogenic species of proteins can spread 
Abstract Huntington’s disease (HD) is an autosomal dom-
inant neurodegenerative disorder of the central nervous sys-
tem (CNS) that is defined by a CAG expansion in exon 1 
of the huntingtin gene leading to the production of mutant 
huntingtin (mHtt). To date, the disease pathophysiology has 
been thought to be primarily driven by cell-autonomous 
mechanisms, but, here, we demonstrate that fibroblasts 
derived from HD patients carrying either 72, 143 and 180 
CAG repeats as well as induced pluripotent stem cells 
(iPSCs) also characterized by 143 CAG repeats can trans-
mit protein aggregates to genetically unrelated and healthy 
host tissue following implantation into the cerebral ventri-
cles of neonatal mice in a non-cell-autonomous fashion. 
I. Jeon and F. Cicchetti have contributed equally to this work.
Electronic supplementary material The online version of this 
article (doi:10.1007/s00401-016-1582-9) contains supplementary 
material, which is available to authorized users.
 * Jihwan Song 
 jsong@cha.ac.kr
1 CHA Stem Cell Institute, CHA University, Room 604, 
CHA Bio Complex, 335 Pangyo-ro, Bundang-gu, 
Seongnam-si 13488, Gyeonggi-do, Republic of Korea
2 Centre de recherche du CHU de Québec (CHUQ), Québec, 
QC G1V 4G2, Canada
3 Département de Psychiatrie and Neurosciences, Université 
Laval, Québec, QC G1V 0A6, Canada
4 Department of Neurology, Seoul National University 
Hospital, Seoul, Korea
5 Département de Médecine Moléculaire, Université Laval, 
Québec, QC G1V 0A6, Canada
6 Ilsong Institute of Life Science, Hallym University, Anyang, 
Korea
578 Acta Neuropathol (2016) 132:577–592
1 3
in a prion-like fashion [4, 11, 22, 35, 36, 38, 41, 44]. 
Indeed, it was subsequently shown that α-synuclein can 
be released and taken up by neurons [13, 19, 23, 24] and 
thereby seed pathology both in vitro and in vivo. Intrac-
erebral inoculation of brain homogenates derived from 
aged α-synuclein transgenic mice, or injection of synthetic 
α-synuclein-preformed fibrils, accelerates the formation of 
α-synuclein protein aggregates and precipitates neurologi-
cal dysfunction in rodents [4, 15, 22, 26, 27, 35, 44]. In 
addition to the possibility of an intercellular trans-synaptic 
transport of proteins, α-synuclein has been shown to co-
localize with markers of endosomes and exosomes, which 
could represent a route by which it is transferred [2, 4, 11, 
16, 22, 35, 38, 41, 44].
However, in Huntington’s disease (HD), like in all trinu-
cleotide disorders of the CNS, the classical dogma purports 
that the abnormal protein, in this case mutant huntingtin 
(mHtt), causes cellular dysfunction through a cell-auton-
omous manner that results in aggregation, inclusion body 
formation and cell death [8, 13, 19, 23, 24, 48]. Yet, despite 
the fact that HD is an autosomal dominant disorder, recent 
publications have challenged the assumption that the 
pathology emerges from a purely cell-autonomous process 
[3, 7, 37]. The severity of the clinical features—based on 
movement disorders, cognitive dysfunction and psychiat-
ric problems [39]—in the presence of an expanded CAG 
repeat variably correlate with disease phenotype, which 
implies that additional extrinsic factors are responsible for 
the severity of symptoms and the timing of disease onset 
[18]. The recent observation of aggregates of the mHtt 
gene product within fetal striatal allografts in patients with 
HD provides strong evidence for the existence of non-cell-
autonomous mechanisms of action for pathological protein 
spread in genetic disorders as well [7]; a theory which is 
gaining support both in vitro and in vivo [12, 13, 19, 26, 
27, 30, 31].
Here, we addressed the contribution of non-cell-auton-
omous mechanisms of mHtt spread to disease onset and 
development by transplanting human fibroblasts, induced 
pluripotent stem cells (iPSCs) or exosomes derived from 
HD cases expressing various CAG repeat lengths into nor-
mal wild-type neonatal mice. The data collected provide 
compelling evidence that the intrinsic expression of the 
mutated gene is not needed for the HD-related phenotype 
nor pathology to develop.
Materials and methods
Establishment of fibroblast cell lines
Skin fibroblasts were isolated from a 6-year old male juve-
nile HD patient carrying 143 CAG repeats (HD143F). The 
procedures were approved by the Institutional Review 
Board of Seoul National University Hospital (Seoul, 
Korea). Two additional fibroblast lines were obtained 
from Coriell Cell Repositories (Camden, NJ, USA), origi-
nating from a 20-year old female HD patient carrying 72 
CAG repeats (HD72F; Cat. No.: GM04281) or an addi-
tional 6-year old male juvenile HD patient carrying 180 
CAG repeats (HD180F; Cat. No.: GM09197). As a control, 
embryonic fibroblasts (hEF) obtained from aborted human 
embryos were used following approval by the Institutional 
Review Board of CHA Gangnam Medical Center (Seoul, 
Korea). Fibroblasts were maintained in Dulbecco’s Modi-
fied Eagle’s Medium (DMEM) high glucose (Welgene, 
Korea), supplemented with 10 % fetal bovine serum (Inv-
itrogen) and 1 % penicillin/streptomycin (Sigma-Aldrich) 
grown on 0.2 % gelatin-coated culture dish. For the trans-
plantation of fibroblasts, they were dissociated using 
0.25 % trypsin–EDTA and resuspended in DMEM high 
glucose with 30 µM Y-27632 (Tocris) following a centrifu-
gation at 1200 rpm for 3 min.
Genomic DNA isolation and PCR
Given that the focus of the manuscript is on the experiments 
performed with the 143 CAG fibroblasts, we will primar-
ily describe these cells. Genomic DNA was, therefore, iso-
lated from hEF and HD143F using genomic DNA isolation 
buffer (10 mM Tris–HCl, pH 8.0, 200 Mm NaCl, 10 mM 
EDTA, 0.5 % SDS, 100 µg/ml Proteinase K (Roche), incu-
bated at 55 °C for 3 h, followed by phenol/chloroform 
extraction and ethanol precipitation. The purified genomic 
DNA was dissolved in TE buffer (10 mM Tris–HCl, pH 8.0, 
1 mM EDTA) and used to amplify the htt gene. PCR ampli-
fication was performed in primeSTAR premix (Takara), 
Pfu HQ buffer (GeneAll) using primers designed to anneal 
638 and 1010 bps for hEF and HD143F, respectively. The 
primer’s sequences were as follows: forward primer (Htt-
UTR FW) 5′-ATTGGCAGAGTCCGCAGGCTAG-3′ and 
reverse primer (Htt intron 1-2 Rev) 5′-GCTGGGT-
CACTCTGTCTCTG-3′ (Supplemental Fig. 1a). Addi-
tional characterizations included the expression of mHtt 
using EM48, karyotypes and growth curves (Supplemental 
Fig. 1a).
Preparation of iPSCs
HD143-iPSCs were generated using the episomal method 
[34]. Briefly, HD143F and hEF were electroporated with 
the episomal vectors using Neon™ Transfection System 
(Invitrogen), and the resulting iPSC colonies were main-
tained and expanded, which formed stable iPSC lines after 
passage 10 (P10). Established iPSC lines were examined 
for pluripotency using the RT-PCR analysis. They were 
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immunostained with antibodies against pluripotency mark-
ers, such as Oct4, SOX2, Tra-1-81, and SSEA4 (data not 
shown) as well as for the expression of mHtt using EM48 
(Supplemental Fig. 2). We further performed karyotype 
analysis, based on GTG-banding patterns (Supplemental 
Fig. 2). After the characterization of established iPSC lines, 
each iPSC line was differentiated into neural precursor 
cells (NPCs) according to previously published methodol-
ogy [30] for implantation into the neonatal mouse brain.
Injection of fibroblasts or iPSC‑derived NPCs into the 
neonatal mouse brain
Adult CF-1 mice were purchased from the Jackson Labo-
ratory and housed in a temperature and light-controlled 
environment (22 °C, a 12-h cycle) at the CHA University 
animal research center. Mouse pups were cryoanesthetized 
at post-natal day 2 (P2) after direct contact with ice for 
3 min. The anesthetised pup’s head was gently held, and 
the ventricles were visualized by transillumination, keep-
ing the head over a light source. A total of 100,000 fibro-
blasts (HD72F, HD143F, HD180F or hEF cells) or iPSCs 
(HD143-iPSC or epi-iPSC cells) resuspended in a 1 µl 
volume—after overnight incubation with 1 µg/ml bisben-
zimide (Hoechst 33342, Sigma-Aldrich) at 37 °C—were 
injected into the lateral ventricles bilaterally using a 29G 
Hamilton syringe (Hamilton Company). The transplanta-
tion procedure was carried out quickly to minimize pups 
handling (approximately 5 min per pup) and, therefore, 
to reduce the risks of cannibalism when animals were 
returned to their mothers. All experiments were performed 
in accordance with the guidelines of the CHA University 
IACUC (Institutional Animal Care and Use Committee; 
IACUC090012).
Behavioural tests
Motor and cognitive deficits were assessed in mice that 
received either HD patient-derived fibroblasts or iPSCs. 
Clasping and simple swim test were evaluated in mice 
transplanted with HD143F at 30 weeks of age (Fig. 1a), 
while the simple swim test, forced swim test, rotarod and 
grip strength tests were performed in mice that received 
HD72F, HD180F and HD143-iPSCs. In these experi-
ments, the behavioural measures were taken at 34, 36 and 
38 weeks of age (Supplemental Fig. 3 a, d).
Fig. 1  Development of HD-associated behavioural phenotypes fol-
lowing intraventricular injection of HD patient-derived fibroblasts. a 
Timeline of in vivo experimentation using fibroblasts derived from an 
HD patient carrying 143 CAG repeats. b Representative images of the 
clasping test as well as trajectories on the simple swim test. c Quan-
tification of clasping reveals the manifestation of an HD phenotype 
in mice transplanted with fibroblasts collected from an HD patient 
(HD143F) compared to animals in receipt of control cells (hEF) at 
30 weeks post-implantation. Plotting of the time to reach the plat-
form and swimming direction scores (navigational memory) further 
reveals cognitive-related deficits in mice transplanted with fibroblasts 
positive for the HD gene at the same time point. Values are expressed 
as mean ± SEM. Statistical analyses were performed using the Stu-
dent’s t test. *p < 0.05 compared to hEF. The number of mice used in 
each group is indicated in each column of the graphs. HD143F fibro-
blasts derived from an HD patient with 143 CAG repeats; hEF human 
embryonic fibroblasts; P2 post-natal day 2; w weeks
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Clasping test
The clasping test, a classic measure of the HD pheno-
type [10], was performed by suspending the mice by the 
tail 10 cm above the cage for 1 min. Mice demonstrat-
ing HD-like features clasped both front and hind legs and 
twisted their body [25]. Animals were scored using a scale 
that ranged from 0 (the hindlimbs consistently splayed 
outward) to 3 (both hindlimbs are entirely retracted and 
touching the abdomen for more than 50 % of the time 
suspended).
Simple swim test
The simple swim test was chosen as a measure of cogni-
tive impairments and procedural learning, as previously 
performed in HD animals [40, 46]. Mice were placed in 
the center of a linear swimming chamber (76 × 13 cm; 
water depth, 9 cm; platform, 6 × 13 cm) facing away 
from the escape platform. The amount of time required to 
reach the platform and the initial swimming direction was 
recorded for each trial. Swimming towards the platform 
was arbitrarily given a score of 0, whereas swimming 
away from the platform was given a score of 1. Mice were 
trained for 3 days with three pairs of two consecutive tri-
als spaced 2 h apart. For each mouse, the average of the 
three trials on the last day of testing was used for the anal-
ysis [40].
Forced swim test
The forced swim test is commonly used to identify depres-
sion-like behaviour but also motility in HD mice [33, 40]. 
This test was conducted by placing the mice in a glass cyl-
inder (25-cm tall × 19-cm wide) filled with warmed water 
(23–25 °C) to a depth of 15 cm for a period of 6 min. The 
test sessions were recorded by a video camera. The last 
4 min of the test session was scored using a time-sampling 
technique to rate the predominant behaviour over 1 s inter-
val. A number of parameters were measured (swimming, 
immobility and climbing).
Rotarod test
We used an accelerating rotarod protocol (San Diego 
Instruments) to test motor coordination and gait changes, 
as routinely performed in the characterization of an HD 
phenotype in mice [10]. Accelerations ranged from 0 
to 45 rpm over a period of 2 min. Mice were trained for 
3 days, two trials per day. Following the training period, 
mice were tested for three consecutive trials in a single day 
and allowed 1.5 h rest time between trials. The rotarod was 
wiped clean with ethanol between each subject and trial.
Grip strength test
Grip strength was finally used as an additional assessment 
of motor function [29]. The apparatus (San Diego Instru-
ments) is comprised of an adjustable grip (6 cm wide, 
0°–45°) connected to the digital gauge. For this measure, 
the mouse was lifted by the tail, so that its forepaws could 
grasp the grip. The mouse was then gently pulled backward 
by the tail until the wire was released. The maximal force 
exerted before the mouse lost its grip was recorded. Each 
mouse was tested for nine trials, and the average of three 
highest scores was used for subsequent analysis.
Post‑mortem analyses
Tissue processing
Mice were sacrificed at 4, 16, 30 and 40 weeks following 
the injection of HD143F (Fig. 1a) or 40 weeks following 
the implantation of HD72F, HD180F or HD143-iPSCs 
(Supplemental Fig. 3a, d). They were subjected to intra-
cardiac perfusion with phosphate-buffered saline (PBS) 
and 4 % paraformaldehyde (PFA) under deep anesthesia 
with 1 % ketamine (30 mg/kg) and xylazine hydrochlo-
ride (4 mg/kg). Brains were collected, post-fixed in 4 % 
PFA overnight and subsequently stored in 30 % sucrose 
for cryoprotection. Coronal 40 µm-thick brain sections 
were obtained using a sliding microtome (Leica), serially 
collected in anti-freeze solutions and kept at −20 °C until 
use for immunohistochemistry/immunofluorescence. In 
this study, only the post-mortem evaluation related to the 
HD143F experiment is presented.
Immunofluorescent staining
Free-floating sections were washed in PBS (2 × 15 min) 
followed by 1 min incubation in PBS containing 1 % 
sodium dodecyl sulfate (SDS). After three additional 
washes in PBS with 0.3 % triton X-100, sections were 
blocked in 5 % normal horse (Vector Laboratories) or 
10 % donkey serum (Sigma-Aldrich) followed by incu-
bation overnight with the primary antibody for either 
CR (1:100, Cat. No. 769914, Swant), DARPP-32 (1:200, 
Cat. No. #2306, clone 19A3, Cell Signaling), ED1 
(1:100, Cat. No. MAB1435, Millipore), EM48 (1:50, 
Cat. No. MAB5374, Millipore), GFAP (1:100, Cat. No. 
G5601, Promega), Iba1 (1:100, Cat. No. 019-19741 
Wako), MAP2 (either 1:200, Cat. No. AB5622, Mil-
lipore or 1:100, Cat. No. 17490-1-AP, Protein Tech), 
hMito (1:200, Cat No. MAB1273, clone 113-1, Mil-
lipore), MW7 (1:100, obtained from the Developmen-
tal Studies Hybridoma Bank), NeuN (1:500, Cat. No, 
MAB377, clone A60, Millipore) or Ubiquitin (1:1000; 
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Cat. No. Z0458, Dako). Following a series of washes 
in PBS, sections were incubated with the appropriate 
fluorescently-conjugated antibodies for 2 h at room tem-
perature. Finally, following three additional washes, sec-
tions were incubated in PBS containing 1 µg/ml DAPI 
(Roche), washed and coverslipped with Vectashield 
(Vector Laboratories).
Note that for the MAP2-MW7 double immunofluores-
cent staining, sections were further incubated in 4 % PFA 
pH 7.4 for 1 h, followed by three washes in KPBS, and 
blocked in 1 % BSA, 0.4 % Triton X-100 and 5 % NGS 
diluted in KPBS for 30 min. Incubation in the primary anti-
body exceeded 48 h at 4 °C. After three additional washes 
in KPBS, the sections were incubated in the appropri-
ate secondary antibody diluted in a blocking solution and 
counterstained with DAPI 0.022 %.
Confocal laser‑scanning microscopy
Confocal laser scanning microscopy was performed using 
LSM510 (Carl Zeiss) and Olympus FV500 (Olympus 
America Inc.) confocal laser-scanning microscopes. Images 
were acquired by sequential scanning and optimized by a 
two-frame Kalman filter and analyzed using the Fluoview 
SV500 imaging software 4.3 (Olympus America Inc., Mel-
ville, USA).
Immunohistochemistry
A similar protocol as described above was used for the 
immunohistochemical staining of DARPP-32 (1:200). 
Following incubation with the primary antibody, sections 
were incubated with biotinylated anti-rabbit secondary 
antibody (1:500, Vector Laboratories) and the avidin–bio-
tin–peroxidase complex (Vector Laboratories) according 
to manufacturer’s instructions. Sections were developed in 
0.05 % 3-3′-diaminobenzidine tetrahydrochloride (DAB) 
and 0.003 % hydrogen peroxide in 0.1 M Tris–Cl (pH 7.5). 
Following the DAB reaction, sections were mounted on 
glass slides. All sections were finally air-dried, dehydrated 
in ascending grades of ethanol, cleaned in xylene, and cov-
erslipped with DPX mounting media (EM Science). Images 
were acquired with a phase-contrast microscope (Eclipse 
E600, Nikon).
Quantification of DARPP‑32, GFAP and ED1 
immunostaining
The counts of DARPP-32+, GFAP+ or ED1+ cells were 
performed by sampling nine different areas (1 mm × 1 mm 
each) of the striatum from three different animals per 
group at 4, 16, 30 and 40 weeks (for DARPP-32) or 30 
and 40 weeks (for GFAP and ED1) post-injection using the 
ImageJ software (Image J, NIH).
Quantification of EM48 immunofluorescent staining 
intensity
Immunoflurorescent staining intensity for EM48-positive 
signals was measured from three different regions of stri-
atum or cortex in the mouse brains at 40 weeks follow-
ing implantation with HD143F or HD143-iPSC using the 
ImageJ software, on maximum projection images result-
ing from the superimposition of the single z-stacks, as 
described previously [28].
Co‑culture of mouse neural stem cells with fibroblasts
Neural stem cells (NSCs) were isolated from the corti-
cal region of developing mouse (FVB/NJ) at embryonic 
day 12.5 and were maintained in NSC medium contain-
ing DMEM/F12 (Gibco), N2 supplement (1X, Gibco), 
bFGF (10 ng/ml, Peprotech), EGF (10 ng/ml, Millipore) 
and antibiotic/antimycotic solution (1X, Welgene, Korea) 
on tissue culture dishes pre-coated with poly-l-ornithine 
(PLO; 15 µg/ml, Sigma-Aldrich) and laminin (5 µg/ml, 
Sigma-Aldrich). To induce neural differentiation, NSCs 
were detached using TrypLE select (1X, Gibco), and the 
dissociated cells (1 × 106 cells) were transferred to 60 mm2 
bacterial Petri dishes (SPL, Korea) for 2 days to induce the 
formation of neurospheres (NSs). Two-day old NSs were 
transferred to four-well plates (Nunc) containing pre-plated 
hEF or HD143F cells with the initial seeding density of 
5 × 104 cells per well (approximately 15–20 NSs in each 
well). Medium was changed every other day. Transferred 
NSCs were further differentiated for one week in the 
medium containing DMEM/F12 (Gibco), 0.1 mM NEAA 
(Gibco), 0.1 mM β-mercaptoethanol (Invitrogen), 0.2 mM 
ascorbic acid (Sigma-Aldrich), N2 supplement (Gibco) 
and BDNF (10 ng/ml, R&D Systems). After 1 week, dif-
ferentiated cells were fixed using 4 % paraformaldehyde 
for 15 min, followed by washes with PBS containing 0.1 % 
Triton X-100 for three times. Immunocytochemistry was 
performed using antibodies against MAP2 (1:200, Milli-
pore) and EM48 (1:100, Millipore).
Exosome extraction and characterization
Exosomes were isolated by ExoQuick-TC™ Exosome Pre-
cipitation Solution (System Biosciences) from hEF and 
HD143F following the manufacturer’s protocol. Briefly, 
supernatants of media containing exosome-free fetal bovine 
serum was collected from fibroblasts after 24 h in cul-
ture and mixed with ExoQuick-TC exosome Precipitation 
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Solution. After refrigeration overnight, the mix was cen-
trifuged at 1500×g for 30 min. Supernatant was removed, 
and the pellet was resuspended in lysis buffer for western 
blot analysis.
Western blot analysis
Cells and exosomes were lysed in ice-cold cell lysis 
buffer containing 50 mM Tris/HCl (PH7.5), 2 mM 
EDTA, 150 mM NaCl, 1 % (v/v) Triton X-100, com-
plete™ proteinase and phosphatase inhibitors (Roche), 
as described previously [5]. Lysates were loaded and 
subjected to SDS–polyacrylamide (4–20 %) electropho-
resis and electroblotted onto PVDF membranes. After 
blocking in 5 % non-fat dry milk, membranes were 
incubated with mouse anti-polyglutamine (1C2, Cat. 
No. MAB1574, Millipore), mouse anti-total huntingtin 
(4C8, Cat. No. MAB2166, Millipore) and mouse anti-
mutant huntingtin (EM48; 1:1000) antibodies. Exosomes 
were identified with the antibodies raised against CD9 
(1:1000, Cat. No. EXOAB-CD9A-1, Systems Bio-
sciences), CD63 (1:1000, Cat. No. EXOAB-CD63A-1, 
Systems Biosciences), CD81 (1:1000, Cat. No. EXOAB-
CD81A-1, Systems Biosciences) and HSP70 (1:1000, 
Cat. No. EXOAB-Hsp70A-1, Systems Biosciences). 
Membranes were incubated with the appropriate second-
ary antibody (goat anti-mouse or anti-rabbit) according 
to the manufacturer’s instructions, followed by the addi-
tion of the chemiluminescent detection reagent (Mil-
lipore). Bands were visualized using a ChemiDoc™ 
XRS + system (Bio-Rad) and quantified using the image 
lab software (Bio-Rad).
Cell line and culture conditions
The SH-SY5Y (human neuroblastoma) cell line was cul-
tured in DMEM (Sigma-Aldrich) supplemented with 10 % 
heat inactivated FBS (Sigma-Aldrich), 2 mM l-glutamine 
(Invitrogen) and 1X penicillin/streptomycin solution 
(Sigma-Aldrich). Cells were plated in 10 cm2 petri dishes 
and transfected using FastFect (Feldan) according to the 
manufacturer’s instructions. Three different constructs were 
introduced into the cells. cDNA coding for human hunting-
tin Exon 1, harboring different CAG repeats (Q19 or Q103) 
fused to GFP as well as cDNA coding for GFP alone were 
cloned into the pAAV-CMV-MCS backbone (Stratagene). 
All constructs were verified by sequencing. Twenty hours 
post-transfection, the culture medium was replaced with 
DMEM without FBS for an additional 24 h after which 
cells, and media were collected. Cells were resuspended in 
lysis buffer containing phosphatase and protease inhibitors 
(Thermo Scientific). Part of the collected medium was used 
to perform an LDH assay (Life technologies) according 
to the manufacturer’s instructions, while the remaining 
medium was used for exosome extraction.
Exosome extraction from SH‑SY5Y cells conditioned 
media
The media were centrifuged for 30 min at 10,000×g at 
4 °C to eliminate cell debris and then concentrated using 
Amicon Ultra 4 ml centrifugal filters prior to exosome iso-
lation, as previously described [45]. Briefly, the concen-
trated medium underwent a series of ultracentrifugation. 
After a first centrifugation at 20,000×g for 1 h and 30 min 
at 4 °C, the medium was collected and centrifuged again at 
100,000×g for 1 h at 4 °C. The pellet containing exosomes 
were finally resuspended in phosphate buffer. The presence 
of exosomes was validated with a Zetasizer Nano series ZS 
(Malvern) using the software Zetasizer 7.02 [32].
Western blot analysis from SH‑SY5Y cells
Laemmli buffer was added to the cell extract, to the con-
centrated medium as well as exosome preparation and ulti-
mately heated at 95 °C for 15 min. Samples were loaded 
and subjected to SDS-polyacrylamide (10 %) gel elec-
trophoresis. Proteins were immunoblotted onto 0.45 µm 
Immobilon PVDF membranes (Millipore) and blocked 
in 5 % non-fat dry milk and 1 % BSA in PBS-tween. 
Membranes were incubated with mouse anti-polyglu-
tamine (1C2; 1:1000), rabbit anti CD-63 (1:1000; Cat No. 
ab199921, Abcam) and anti β-actin (1:10,000; Cat No. 
G043, ABM Inc.) using appropriate secondary antibodies, 
such as goat anti-rabbit or anti-mouse (1:25,000; Jackson 
Immunoresearch), followed by the addition of the chemi-
luminescence reagents (Luminata; Millipore). Band inten-
sities were quantified using a myECL imager (Thermo 
Scientific).
Incubation of SH‑SY5Y cells in conditioned media 
and detection of incorporated mHtt
HEK cells transiently overexpressing GFP, GFP-mHtt-
Q19 or GFP-mHtt-Q103 were cultured in DMEM (Sigma-
Aldrich) supplemented with 10 % heat inactivated FBS 
(Sigma-Aldrich), 2 mM l-glutamine (Invitrogen) and 
penicillin/streptomycin (Sigma-Aldrich). Forty-eight 
hours post-transfection, the conditioned media were col-
lected and centrifuged at 10,000×g for 10 min to remove 
cell debris. The supernatant was added to SH-SY5Y neu-
roblastoma and incubated for 5 days. The conditioned 
media were added three times over 5 days. After incuba-
tion, SH-SY5Y cells were treated with trypsin for 5 min to 
remove extracellular proteins and were collected and lysed 
in 1X lysis buffer. The total protein fraction was separated 
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in SDS-polyacrylamide (10 %) gel and incorporated mHtt 
from the conditioned media that were detected by western 
blot using anti-mHtt (EM48) and anti-GFP antibodies.
Treatment of NSCs with exosomes
NSCs, prepared as described above, were cultured in 
ultra-low attachment tissue culture dishes. One day later, 
neurospheres were transferred onto 12 mm glass coverslip 
pre-coated with poly-l-ornithine (PLO; 15 µg/ml, Sigma-
Aldrich) and laminin (5 µg/ml, Sigma-Aldrich) in NSC 
medium. Following the attachment of the neurospheres, 
the culture medium was replaced with a medium contain-
ing DMEM F12, 1 % NEAA, 10 mM β-mercaptoethanol 
and 1 % antibiotic antimycotic solution supplemented 
with 1X N2, 2 mM l-glutamine, 3 mM d-glucose, 0.2 mM 
ascorbic acid and 10 ng/ml BDNF (NS medium) and 
250 µg/ml of exosomes derived from HD143F and hEF 
(see timeline Fig. 5e). The medium was changed every 
other day. At day 4, the cells were fixed and immu-
nostained for MAP2 (1:200) and anti-EM48 (1:100).
Injection of exosomes into the neonatal mouse brain
The in vivo experiments pertaining to the injections of 
exosomes derived from the HD patient carrying 143 CAG 
repeats or from human embryonic fibroblast (hEF) (control) 
were performed using identical procedures as described 
above (see Sect. “Injection of fibroblasts or iPSC-derived 
NPCs into the neonatal mouse brain”). Exosome suspen-
sions were injected into both ventricles (5 µg/each ven-
tricle; a total of 10 µg per animal) using a 31G Hamilton 
syringe.
Image preparation and statistical analyses
All images were prepared for illustration using Adobe Pho-
toshop CS5 and Adobe Illustrator CS5. Data were analyzed 
with the one-factor analysis of variance (ANOVA) followed 
by a Tukey post hoc test or Student’s t tests, using the Sta-
tistical Analysis System (Enterprise 4.1, SAS Korea, Seoul 
Korea). Significance was accepted at the 95 % probability 
level. Data are presented as mean ± SEM.
Results
Injection of HD‑ patient‑derived fibroblasts or iPSCs 
leads to HD‑related motor and cognitive impairments 
in wild‑type mice
We first evaluated the potential of HD patient-derived 
fibroblasts carrying the entire 170 kb genomic locus of the 
human Htt gene to generate an HD-associated phenotype 
in wild-type mice. Pathological fibroblasts displayed an 
amplification of exon 1 with 143 CAG repeats (HD143F), 
while controls (hEF) carried 19 CAG repeats (Supplemen-
tal Fig. 1a). The presence of the mutation was confirmed 
by PCR (Supplemental Fig. 1a), western blot analyses with 
an antibody directed against the polyQ expansion on exon 
1 of the gene (Supplemental Fig. 1b) and immunoflurores-
cent staining using the mHtt-specific antibody EM48 (Sup-
plemental Fig. 1c). Both HD143F and hEF showed normal 
karyotypes (Supplemental Fig. 1d), although HD143F was 
shown to grow slowly, compared with hEF (Supplemental 
Fig. 1e).
Upon phenotypic confirmation, HD143F or hEF cells 
were injected bilaterally into the lateral ventricles of wild-
type pups at post-natal day 2 (P2), followed by behavioural 
measures (Fig. 1a). At 30 weeks, animals transplanted with 
HD143F cells displayed a measurable abnormal clasp-
ing response characteristic of HD mice [14] (Fig. 1b, c; 
p < 0.05 (see also Supplemental Video 1)). In the simple 
swim test—a measure of cognitive impairments and pro-
cedural learning—animals transplanted with HD143F 
required twice as much time to reach the visible escape 
platform than controls. They also displayed aberrant swim-
ming direction patterns, reminiscent of impairments in both 
motor coordination and navigational memory (Fig. 1b, c; 
p < 0.05 (see also Supplemental Video 2)).
These results were corroborated using additional clones 
from HD patients carrying various CAG repeat lengths 
(Supplemental Fig. 3a–c). Using an identical experimen-
tal approach, newborn wild-type mice injected with fibro-
blasts derived from HD patients with either 72 or 180 CAG 
repeats (HD72F or HD180F) developed an HD behavioural 
phenotype over time (Supplemental Fig. 3a–c). At 34 weeks 
post-injection and onwards, animals began to show impair-
ments on the simple swim test (time to reach the platform), 
the forced swim test (immobility time) (Supplemental 
Fig. 3b, c), the grip strength (Supplemental Fig. 3c), and 
the rotarod (latency to fall) (Supplemental Fig. 3c). Aside 
from the forced swim test, which revealed greater impair-
ments in mice treated with the HD180F (p < 0.05), there 
was no significant difference between the severity of defi-
cits created with either cell type. Sham animals that under-
went the same surgical procedures—omitting the injection 
of the cells or a corresponding vehicle—did not present 
with any behavioural impairments (Supplemental Fig. 3c).
These observations were further supplemented using 
an additional cell type, i.e., induced pluripotent stem cells 
derived from the same HD patient with 143 CAG repeats 
(HD143-iPSC) or controls (epi-iPSC) which were injected 
bilaterally into the lateral ventricles of wild-type pups at 
P2 (Supplemental Fig. 3d). At 36 and 38 weeks, animals 
transplanted with HD143-iPSC cells displayed measurable 
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behavioural deficits characteristic of HD mice (Supplemen-
tal Fig. 3e, f; p < 0.05). In the simple swim test, animals 
transplanted with HD143-iPSC cells required significantly 
more time to reach the escape platform (see also Supple-
mental Video 3). They further displayed aberrant swim-
ming direction patterns (Supplemental Fig. 3e, f; p < 0.05; 
see also Supplemental Video 3), impaired mobility, as 
revealed by the forced swim test (Fig. 3e, f; p < 0.05; see 
also Supplemental Video 4) as well as impairments in the 
grip strength test when compared to their control counter-
parts (Supplemental Fig. 3f; p < 0.05), although there were 
no significant differences between groups using the rotarod 
test (Supplemental Fig. 3f). Taken together, detectable 
abnormalities on these measures indicate the development 
of HD-like cognitive and motor-related features in mice 
transplanted with various cells carrying different clones of 
the mutated gene.
Progressive striatal neuronal loss following  
intraventricular injection of HD patient‑derived 
fibroblasts
To evaluate whether the observed motor and cognitive 
disturbances reflected an underlying neuropathological 
phenotype, we assessed the presence of mHtt focusing 
on one of the cell-type implanted, the HD patient-derived 
fibroblasts, using immunoflurorescent stainings for EM48 
and hMito, human mitochondria (hMito), at 4 (data not 
shown), 16, 30 and 40 weeks post-injection (Fig. 2a). At 
16 weeks post-transplantation, EM48 staining was closely 
associated with that of hMito but as time elapsed, hMito 
levels diminished and almost entirely vanished. EM48+ 
mHtt aggregates were scarcely found within the trans-
planted human fibroblasts but were detected mainly within 
the host parenchyma (Fig. 2a, 40w), indicating the transfer 
of the mHtt gene product irrespective of the survival of the 
donor cells.
We then investigated whether grafted human fibroblasts 
had an impact on the neighbouring striatum, in particular, 
the striatal medium spiny neurons, a neuronal population 
severely affected in HD. Consistent with the behavioural 
data (Fig. 1b), cell loss was apparent at 30 weeks follow-
ing the transplantation of HD patient-derived fibroblasts 
and further progressed to 40 weeks post-transplantation, 
the ultimate time point we analyzed (Fig. 2b, c; p < 0.05, 
p < 0.005). In mice receiving control human fibroblasts, 
no changes in the number of DARPP-32+ neurons were 
observable at any of the time points analyzed (Fig. 2c). To 
assess the specificity of cell loss, we further stained brain 
sections for calretinin (CR), present in subpopulations of 
interneurons which are spared in HD [6]. As observed in 
HD pathology, CR-positive neurons, either cortical or stri-
atal (Fig. 2e), did not show morphological changes nor 
compromised survival. Finally, to ensure that the loss of 
medium spiny neurons was not due to the proliferation of 
fibroblasts, sections were further stained for Ki67, a marker 
of cell proliferation, which demonstrated the presence of 
Ki67-positive cells was restricted to the ventricles, the site 
of injection. None of our observations revealed the pres-
ence of tumour formation (Fig. 2f).
Evidence of mHtt transfer from HD patient‑derived 
fibroblasts to host striatal cells
At 30 and 40 weeks post-transplantation, mHtt could be 
found within the host striatal neurons. Using triple immu-
nofluorescent staining and confocal microscopy, EM48+ 
aggregates were detected within DARPP-32+ cellular ele-
ments, suggesting that mHtt had effectively been trans-
ferred from grafted cells of human origin to the host stria-
tum at 30 (Fig. 3a) and 40 weeks post-injection (Fig. 3b, d) 
but also to the host cortex (Fig. 3c). We supplemented these 
observations using anti-MW7 and anti-ubiquitin antibodies, 
which confirmed that mHtt aggregates were indeed found 
within the host neurons, as demonstrated with both MAP2 
and NeuN markers that are not expressed by human fibro-
blasts (Fig. 3e–h). A quantification of the relative immuno-
fluorescent staining intensity for EM48 also revealed that 
mHtt aggregates were more abundant in the striatum than 
in the cortex (Fig. 3i). To validate the specificity of these 
findings, double immunofluorescent staining was also per-
formed for DARPP-32 and EM48 in mice implanted with 
hEF control cells which remained devoid of mHtt staining 
(Fig. 3j, k).
Implanted HD fibroblasts lead to a progressive gliosis 
and inflammation within the host brain
In addition to the loss of DARPP-32+ medium spiny neu-
rons and the formation of EM48+ mHtt, increased gliosis 
and inflammation are evident in HD. Similarly, we observed 
that the significant striatal neuronal loss provoked by the 
injection of HD143F cells was accompanied by a signifi-
cant increased gliosis in the vicinity of the lateral ventri-
cles, the site of injection, with a gradient of activated glial 
cells that changed as a function of distance from transplant 
site (Fig. 4a). Indeed, a significant augmentation in the 
number of astrocytic (GFAP+) and microglial (ED1+) cells 
was quantified at both 30 and 40 weeks post-transplantation 
(Fig. 4b, c; p < 0.05, p < 0.005) and these cells were seen to 
populate the space originally occupied by the striatal tissue 
that had now been lost (Fig. 4d). Taken together, these find-
ings show that human-derived mHtt aggregates can spread 
in the newborn mouse brain and translate into HD-related 
behavioural impairments, neuronal loss and gliosis through 
adulthood (Fig. 4e).
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Fig. 2  Progressive and targeted neuronal loss following intraven-
tricular injection of HD patient-derived fibroblasts. a Immunoflu-
rorescent staining of mHtt (EM48; green) and human mitochon-
dria (hMito; red) demonstrating the expression of mHtt within the 
implanted HD143F cells at earlier time points (16 and 30 weeks 
post-injection; indented arrowheads) and the expression of mHtt 
aggregates alone (no longer associated with the hMito marker; larger 
arrowheads) at the later time points evaluated (30 and 40 weeks post-
implantation). b Representative images of the immunohistochemical 
staining for DARPP-32 revealed with the chromogen diaminoben-
zidine (DAB) in the striatum of mice that received either hEF or 
HD143F cells. c Quantification of the progressive DARPP-32 striatal 
neuronal loss in mice that received HD143F or hEF at different time 
points. Values are expressed as mean ± SEM. *p < 0.05; **p < 0.005 
compared to hEF group. The number of mice quantified in each 
group is indicated in each column of the graphs. d The atlas section 
of the mouse brain illustrates the area where images depicted in a 
and b were acquired (red square). e Sections were further stained for 
CR (red), present in subpopulations of interneurons, in combination 
with MAP2 (green) or DARPP-32 (green) and confirmed that, as in 
HD, interneurons are spared from pathology. This was exemplified in 
both the cortex (e, left panels) and in the striatum (e, right panels). f 
Finally, sections were stained for the presence of proliferating cells 
using Ki67 (green) and DAPI (blue) in the vicinity of the injection 
site (lateral ventricle) and confirmed the absence of tumour formation 
following the implantation of HD patient-derived fibroblasts. Scale 
bars a = 50 µm; b = 25 µm; e = 50 µm; f = 30 µm. CR calretinin; 
DAPI 4′,6-diamidino-2-phenylindole; DARPP‑32 dopamine- and 
cAMP-regulated phosphoprotein, Mr 32 kDa; HD143F fibroblasts 
derived from an HD patient expressing 143 CAG repeats; hEF human 
embryonic fibroblasts; hMito human mitochondria; LV lateral ventri-
cle; MAP2 microtubule associated protein 2; w weeks
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Impact of secreted mHtt on cell morphology 
and neuronal differentiation
The identification of mHtt within host neurons suggests 
that mHtt can be secreted and taken up by neighbouring 
cells. Co-culture of neurons derived from murine NSCs 
with HD143F demonstrated that mHtt aggregates from dis-
eased cells have the ability to infect and detrimentally affect 
normal neurons (Fig. 5a, bottom panels), with observable 
impacts on the morphology of exposed cells which display, 
in part, shorter neurites (Fig. 5a; p < 0.001). In contrast, 
when neurons are co-cultured with normal fibroblasts, neu-
ronal differentiation is typical and no overt morphological 
changes are observed (Fig. 5a, top panels).
Exosomes act as cargos in mHtt release
To determine the potential route by which mHtt is trans-
ferred to recipient cells, we investigated the release of 
extracellular vesicles from fibroblasts and found that, 
indeed, extracellular exosomes are detectable in the cul-
ture media (Fig. 5b). The release of exosomes was con-
firmed by immunoblots performed with different antibod-
ies (HSP70, CD81, CD63, CD9 and CD81), as well as size 
analysis using Zetasizer Nano ZS (Fig. 5d), providing the 
first evidence that mHtt is found within extracellular vesi-
cles (Fig. 5c). We further confirmed these results using the 
human neuroblastoma cell line SH-SY5Y overexpressing 
the exon 1 of Htt carrying 19 or 103 CAG fused to GFP 
Fig. 3  Evidence of cell-to-cell propagation of mHtt. Immunoflu-
rorescent staining for mHtt (EM48; red), MW7 (green) or ubiqui-
tin (green) combined with either DARPP-32 (green), MAP2 (red) 
or NeuN (red) reveals the propagation of mHtt from implanted 
HD patient-derived fibroblasts into both host striatal (a, b, d, f) and 
cortical cells (c, e, g, h) at 30 and 40 weeks post-transplantation, as 
assessed by confocal microscopy. The atlas section of the murine 
brain illustrates areas where images were acquired (red squares). 
Quantification of the relative intensity of the immnofluorescent 
EM48 staining further revealed that mHt aggregates were more 
abundant in the striatum than in the cortex (i). Values are expressed 
as mean ± SEM. Statistical analyses were performed using the Stu-
dent’s t test. ***p < 0.001 compared to STR. The number of mice 
quantified in each group is indicated in each column of the graphs. 
Triple immunofluorescence for EM48, DARPP-32 and DAPI in mice 
injected with hEF showed, as expected, the absence of mHtt aggre-
gates (j, k). Scale bars a, b = 20 µm; c, d = 50 µm; e = 10 µm; 
f = 20 µm; g, h = 25 µm; j, k = 20 µm). CTX cortex; DAPI 
4′,6-diamidino-2-phenylindole; DARPP‑32 dopamine- and cAMP-
regulated phosphoprotein, Mr 32 kDa; HD143F fibroblasts derived 
from an HD patient expressing 143 CAG repeats; hEF human embry-
onic fibroblasts; NeuN neuronal nuclei; STR striatum; w weeks
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or GFP alone (Supplemental Fig. 4a). The expression of 
mHtt was detected not only intracellularly but also in the 
extracellular particles identified using the anti-CD63 anti-
body (Supplemental Fig. 4c). The release of exosomes was 
further validated with Zetasizer Nano ZS (Supplemental 
Fig. 4d). The expression of the plasmids did not affect cell 
viability as demonstrated by the LDH assay (Supplemental 
Fig. 4b), confirming that the presence of mHtt in the extra-
cellular media is not due to cell death.
To assess whether secreted mHtt is able to propagate 
from the extracellular milieu to recipient cells, we exposed 
SH-SY5Y cells to the conditioned media of HEK cells 
overexpressing GFP, GFP-mHtt-Q19 or GFP-mHtt-Q103. 
After 5 days of incubation, we analyzed the SH-SY5Y cells 
total protein fraction by western blot. The results revealed 
the presence of exogenous mHtt protein (Q19 and Q103) 
in recipient cells (Supplemental Fig. 4e). Using an anti-
GFP antibody, we strictly detected mHtt, as no signal was 
observed for GFP alone. This suggests that propagation 
from the extracellular milieu to the recipient cells is spe-
cific to mHtt protein (Supplemental Fig. 4e).
To further confirm that exosomal transport could be 
responsible for the propagation of mHtt, neurons derived 
from murine NSC were exposed to HD143F derived 
exosomes for 4 days in culture (Fig. 5e). Differentiated 
cells labeled positively for MAP2 that were exposed to 
vesicles enriched of mHtt depicted the presence of intra-
cellular EM48+ mHtt aggregates (Fig. 5g, g′, g″), while 
Fig. 4  Development of an immune/inflammatory response following 
striatal neuronal loss in mice transplanted with HD patient-derived 
fibroblasts. a Schematic representation of the immune/inflammatory 
response gradient within the striatum illustrating that the strongest 
reaction is in the vicinity of the injection site. b The bar graph shows 
increased astroglial and microglial responses in the striatum of mice 
implanted with HD143F compared to those implanted with hEF at 30 
and 40 weeks post-injection (n = 3 mice per group). c Representa-
tive images of astroglial (GFAP; green) and microglial (ED1; red) 
responses 30 and 40 weeks following the engraftment of fibroblasts 
from HD143F or hEF cells. Values are expressed as mean ± SEM. 
Statistical analyses were performed using the Student’s t test. 
*p < 0.05; **p < 0.005 compared to hEF group. The number of mice 
quantified in each group is indicated in each column of the graphs. 
d Representative images of the astroglial (GFAP; red) and micro-
glial responses (ED1; red) surrounding neuronal (DARPP-32; green) 
and mHtt (EM48; red) staining. e Schematic summarizing the post-
mortem observations following HD143F transplantation with respect 
to the corresponding timeline of analysis. Scale bars b = 30 µm; 
d = 50 µm. CTX cortex; DARPP‑32 dopamine- and cAMP-regu-
lated phosphoprotein, Mr 32 kDa; GFAP glial fibrillar acidic pro-
tein; HD143F fibroblasts derived from an HD patient with 143 CAG 
repeats; hEF human embryonic fibroblasts; LV lateral ventricle; STR 
striatum
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aggregates were not observed in non-treated cells that were 
devoid of aggregates (Fig. 5f). This finding demonstrates 
that cultured cells can internalize exosomes containing 
pathological proteins.
Finally, to test whether exosomes are relevant in the 
transport and dissemination mHtt pathology in vivo, new-
born wilt-type animals were implanted with exosomes 
derived from HD143F, similar to what had been done for 
all the other experiments (Fig. 6a). As observed with the 
injections of fibroblasts and iPSCs, the implantation of 
exosomes derived from HD143F into the ventricle of neo-
natal mice triggered the manifestation of an HD phenotype. 
As early as 8 weeks post-implantation, mice injected with 
exosomes carrying the mHtt gene product began to show 
impairments in the simple swim test, which persisted to 
12 weeks post-implantation, the time point at which we 
ceased to test the animals (Fig. 6b, c). This was accom-
panied by a precipitated latency to fall, as measured by 
the rotarod test, which was noticeable at 10 weeks post-
implantation. Neither sham animals nor mice injected with 
exosomes derived from normal fibroblasts (hEF) showed 
any impairments. In the HD143F exosome-injected ani-
mals, EM48+ mHtt staining was detected in the striatum as 
early as 3 weeks post-implantation and co-localized with 
DARPP-32+ cells of the host (Fig. 6d).
Discussion
Our manuscript provides the first evidence for (1) the 
propagation of the full-length mHtt protein in vivo; (2) the 
development of a robust HD phenotype in wild-type mice, 
both pathologically and behaviorally, using various cells 
derived from a patient with HD and that (3) exosomes can 
cargo mHtt both in vitro and in vivo thus being responsible, 
at least in part, for the propagation of mHtt.
Fig. 5  Release of mHtt by exosomes. a NSCs labeled with MAP2 
(green) displayed mHtt aggregates (EM48+; red) when co-cultured 
with HD143F but not with hEF. Exposure of NSCs to HD143F fur-
ther leads to significant morphological changes, i.e., reduction 
in the neurite length of NSCs (n = 15). Values are expressed as 
mean ± SEM. Statistical analyses were performed using the Stu-
dent’s t test. ***p < 0.001 compared to hEF group. b, c Release of 
exosomes by fibroblasts, as confirmed by the expression of HSP70, 
CD63, CD9 and CD81 (b). mHtt labeled with either 1C2 or EM48 
(c) is found within extracellular vesicles. d Analyses of the exo-
some-enriched fraction using a nano-sizer confirming the size of the 
extracted exosomes. e Timeline of in vitro experimentation involv-
ing co-culture of exosomes and NSCs. f, g NSCs labeled with 
MAP2 (green) and EM48 (red) following exposure to vehicle (f) and 
exosomes derived from HD fibroblasts (g, g′, g″), where images in 
g depict neuronal cells which have internalized exosomes carry-
ing mHtt 4 days into the culture. Scale bars a = 50 µm; f = 50 µm; 
g = 30 µm; g′, g″ = 10 µm. D day; DARPP‑32 dopamine- and 
cAMP-regulated phosphoprotein, Mr 32 kDa: DAPI 4′,6-diamidino-
2-phenylindole; GFP green fluorescence protein; HD143F: fibro-
blasts derived from an HD patient with 143 CAG repeats; hEF human 
embryonic fibroblasts; MAP2 microtubule associated protein 2; mHtt 
mutant huntingtin; NSCs neural stem cells
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Fig. 6  Development of HD-associated behavioural phenotypes fol-
lowing intraventricular injection of exosomes isolated from HD 
patient-derived fibroblasts and evidence of mHtt propagation within 
the brain. a Timeline of in vivo experimentation using exosomes iso-
lated from HD143F. b Representative images of the simple swim test. 
c Plotting of the time to reach the platform as well as the latency to 
fall, as measured by the rotarod test, revealed cognitive and motor-
related deficits in mice transplanted with exosomes carrying mHtt 
in comparison to mice injected with either exosomes derived from 
normal human embryonic fibroblasts or in sham animals. d Triple 
immunoflurorescent staining was further carried out for DARPP-
32, EM48 and DAPI and revealed the propagation of mHtt from 
implanted exosomes isolated from HD patient-derived fibroblasts into 
the host striatum and striatal cells as early as 3 weeks post-implan-
tation. Values are expressed as mean ± SEM. Statistical analyses 
were performed using the Student’s t test. *p < 0.05 and **p < 0.005 
compared to hEF group. Numbers of mice used are as follows: hEF-
exosome, n = 11; HD143F-exosome, n = 11; Sham, n = 9. Scale bar 
d = 20 µm. DARPP‑32 dopamine- and cAMP-regulated phosphopro-
tein, Mr 32 kDa; DAPI 4′,6-diamidino-2-phenylindole; HD143F‑exo 
exosomes isolated from fibroblasts derived from an HD patient with 
143 CAG repeats; hEF‑exo exosomes isolated from human embry-
onic fibroblasts; LV lateral ventricle; P2 post-natal day 2; STR stria-
tum; w weeks
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The cell-autonomous theory of genetic disorders postu-
lates that each cell contains an aberrant gene that contrib-
utes to individual cell pathology [15]. However, we herein 
demonstrate that the transfer of an abnormal gene product 
to genetically unrelated normal tissue is also possible, and 
this, with pathological consequences. This suggests that 
there are additional mechanisms by which genetic dis-
orders can induce disease in tissue that does not actively 
express the pathology. We recently reported that mHtt pro-
tein aggregates are found within fetal striatal transplants 
in HD patients who underwent cell replacement therapy 
[7]. The results we present here are in agreement with this 
finding and a recent report, also by us, demonstrating that 
iPSCs isolated from an HD patient can give rise to HD-like 
cellular pathology after an extended in vivo exposure into 
healthy neonatal brains [21].
There is now mounting evidence that pathological spe-
cies of proteins can be transported trans-synaptically and 
generate relevant disease phenotypes [22, 44]. In vivo 
observations using human neurons implanted in the cortex 
of R6/2 mice has suggested mHtt transfer between synapti-
cally connected neuronal elements [37]. Blocking the syn-
aptic vesicles fusion with botolinum neurotoxins prevented 
the spreading of mHtt in organotypic cultures [37]. The 
identification of pathology remote from the injection sites 
supports an intercellular trans-synaptic protein transmission 
as do studies showing expression of human α-synuclein in 
rodent allografts transplanted in animals expressing human 
α-synuclein [2]. In the latter study, human α-synuclein 
co-localized with markers of endosomes and exosomes 
[2], which could represent the route by which this protein 
is transferred [2, 16]. In addition, exosomal markers have 
been found to be associated with amyloid plaques in Alz-
heimer’s disease (AD) [42] and in vitro models of Amyo-
trophic Lateral Sclerosis have revealed that misfolded 
SOD1 transmission can also occur via released exosomes 
[17]. The identification of mHtt aggregates within our cul-
tured NSCs exposed to mHtt containing exosomes is in line 
with these studies and the development of a full-blown HD 
phenotype in mice injected with exosomes derived from 
diseased fibroblasts strongly supports the role of exosomes 
as vehicle of propagation of HD pathology.
In HD, evidence that mHtt can propagate from cell to 
cell has only recently emerged, with the vast majority of 
results derived from in vitro studies [9, 20, 43, 47]. More 
specifically, various cell types, including neuronal-like 
cells (COS7, HEK293T and PC12 cell lines) have been 
shown to take up and internalize synthetic mHtt aggre-
gates exogenously delivered to the culture milieu [43, 47]. 
In these experiments, aggregates were localized within the 
cytoplasm and associated with proteins involved in the 
quality control of the cell, such as ubiquitin [43]. When 
the synthetic protein was tagged with a sequence mediat-
ing its import into the nuclear compartment, aggregates 
were translocated to the nucleus, where it leads to cell 
death [47]. More recently, another group developed a Bio-
molecular Fluorescence Complementation-based assay 
using non-fluorescent halves of the Venus protein tagged 
to mHtt. When mHtt underwent oligomerization, a fluores-
cent signal was detected. To evaluate whether mHtt could 
propagate from cell to cell, the two halves were expressed 
independently in two separate cell populations. The mixed 
population presented a significant number of fluorescent 
cells, which demonstrated the capacity of the protein to 
migrate from cell to cell but also to act as a seed for further 
protein aggregation [20].
In many sporadic neurodegenerative diseases, such as 
AD and PD, the propagation of abnormal/pathological 
proteins has been proposed to occur in a prion-like fash-
ion [1, 16]. Such prion-like spread has recently been sug-
gested to take place following the phagocytosis of mHtt 
aggregates by glia in a Drosophila model of HD, in which 
engulfed aggregates were granted access to the glial cyto-
plasm where they interacted with soluble Htt, initiating a 
prion-like dissemination of the pathology [36]. This sug-
gested that phagocytosis, otherwise neuroprotective in 
neurodegenerative disorders, could contribute to delete-
rious non-cell-autonomous effects. More recently, mHtt 
was also shown to accumulate at the synaptic terminals 
of the olfactory receptor neurons in another Drosophila 
model of HD with subsequent migration and diffusion 
through the brain. The mutant protein was eventually 
internalized by other neurons, thereby leading to non-
cell-autonomous degeneration. Interestingly, differential 
expression of mHtt in different neuronal populations leads 
to different patterns of propagation [3]. However, criti-
cally, none of these papers have established a direct link 
between protein spread and the development of a full-
blown HD-like phenotype. Our results, therefore, repre-
sent a significant advancement in the possible prion-like 
spread of mHtt by demonstrating that pathology can be 
induced and propagated in the mammalian brain with the 
development of HD in healthy mice, and importantly, 
serve as a new model to further investigate how abnormal 
proteins can be transferred from cell to cell and lead to 
pathological features in vivo.
While our observations do not negate the cell-autono-
mous action of mHtt in HD pathogenesis, they do suggest 
that, even in genetic disorders of the CNS, protein spread 
can occur and may be important in the pathogenic propaga-
tion of disease. Our results have profound implications for 
a whole range of CNS diseases as well as opening up new 
therapeutic avenues for HD and neurodegenerative disor-
ders characterized by similar proteinopathies.
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